Homologous recombination repair deficiency (HRD) occurs in approximately 10% of breast tumors and represents a major targetable vulnerability across multiple cancer types. Impairment of the homologous recombination DNA repair pathway — arising through somatic and germline mutations in homologous recombination repair ge...
Charlotte S. Walmsley, Adela Rodríguez, P. Konstantinopoulos et al.· Journal of Clinical Investig...· 0 citations
Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies sugges...
Adam Nelson, Kelly F. Zheng, C. Wanderley et al.· Journal for ImmunoTherapy of...· 0 citations
Only limited benefit of PD-1/PD-L1 blockade in augmenting PARPi activity is suggested and the need for alternative strategies to sustain PARPi-induced immunity is highlighted.
F. Lynce, Kenichi Shimada, Claudine Isaacs et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.